Dr. Kevin Bennewith obtained his PhD in Pathology and Laboratory Medicine at UBC in 2004 under the supervision of Dr. Ralph Durand at the BC Cancer Agency. During his PhD training, he studied solid tumour physiology with particular emphasis on quantifying poorly oxygenated (hypoxic) tumour cells. He then joined the laboratory of Dr. Amato Giaccia at Stanford University as a post-doctoral scholar, where he was involved in several projects investigating the role of hypoxia-induced secreted proteins in the growth and metastasis of solid tumours. His post-doctoral work included studying the role of connective tissue growth factor in pancreatic tumour growth and using an orthotopic pancreatic tumour model to study the efficacy of chemotherapeutics designed to target hypoxic tumour cells. He also helped to discover a central role for lysyl oxidase in breast cancer metastasis through promoting the recruitment of bone marrow-derived cells to metastatic target organs. Dr. Bennewith was recruited to the BC Cancer Agency in 2008, and since that time his work has been funded by the Canadian Institutes of Health Research, the Terry Fox Foundation, the Cancer Research Society, and the BC Cancer Foundation. Dr. Bennewith is a Distinguished Scientist at BC Cancer and a Professor in Pathology and Laboratory Medicine at UBC.